{"id":"locatop","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Striae"},{"rate":null,"effect":"Telangiectasia"},{"rate":null,"effect":"Local irritation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Locatop (hydrocortisone butyrate) is a potent topical corticosteroid that penetrates the skin and binds to intracellular glucocorticoid receptors, suppressing inflammatory cytokine production and immune cell activation. This reduces erythema, pruritus, and other inflammatory manifestations of dermatological conditions. The formulation is designed for enhanced skin penetration and efficacy in treating localized inflammatory skin disorders.","oneSentence":"Locatop is a topical corticosteroid that reduces inflammation and immune response in skin conditions by binding to glucocorticoid receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:20.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory skin conditions (eczema, dermatitis, psoriasis)"},{"name":"Localized inflammatory dermatological disorders"}]},"trialDetails":[{"nctId":"NCT03437005","phase":"PHASE1","title":"Alternation in the Human Microbiome With Commonly Used Topical Medications","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2013-01-28","conditions":"Healthy","enrollment":24},{"nctId":"NCT07295678","phase":"NA","title":"URGO FilmoCream Eczema + Dermocorticoids in Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"CEN Biotech","startDate":"2026-01-05","conditions":"Atopic Dermatitis","enrollment":44},{"nctId":"NCT02624544","phase":"PHASE4","title":"Proton Pump Inhibitors Use in Patients With Psoriasis","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-01","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT03386032","phase":"PHASE3","title":"8-Week Atopic Dermatitis (AD) Treatment Study","status":"COMPLETED","sponsor":"Procter and Gamble","startDate":"2017-11-27","conditions":"Atopic Dermatitis Eczema","enrollment":65},{"nctId":"NCT03758365","phase":"PHASE1","title":"Evaluation of the Vasoconstriction Properties of MC2-01 Cream","status":"COMPLETED","sponsor":"MC2 Therapeutics","startDate":"2018-11-05","conditions":"Vasoconstriction","enrollment":36},{"nctId":"NCT00690833","phase":"PHASE4","title":"Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2007-08","conditions":"Atopic Dermatitis","enrollment":41},{"nctId":"NCT00828412","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis","status":"COMPLETED","sponsor":"Promius Pharma, LLC","startDate":"2009-03","conditions":"Atopic Dermatitis","enrollment":100},{"nctId":"NCT02732314","phase":"PHASE4","title":"Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Procter & Gamble Beauty","startDate":"2016-03","conditions":"Dermatitis, Atopic, Eczema","enrollment":53},{"nctId":"NCT02286700","phase":"PHASE3","title":"Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis","status":"UNKNOWN","sponsor":"NeoStrata Company, Inc.","startDate":"2014-11","conditions":"Dermatitis, Atopic, Eczema","enrollment":42},{"nctId":"NCT01779258","phase":"PHASE3","title":"Emollients in the Management of Atopic Dermatitis","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2013-02","conditions":"Atopic Dermatitis","enrollment":347},{"nctId":"NCT01935310","phase":"NA","title":"Photoaging Treatment With Imiquimod","status":"COMPLETED","sponsor":"CES University","startDate":"2010-07","conditions":"Photoaging","enrollment":17},{"nctId":"NCT01467362","phase":"PHASE3","title":"Efficacy Emollient on Xerosis in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2011-11","conditions":"Atopic Dermatitis","enrollment":251},{"nctId":"NCT01542138","phase":"PHASE4","title":"Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation","status":"COMPLETED","sponsor":"Universidad Autonoma de San Luis Potosí","startDate":"2011-07","conditions":"Hyperpigmentation","enrollment":28}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"INTERSTITIAL LUNG DISEASE"},{"count":1,"reaction":"CARDIOPULMONARY FAILURE"},{"count":1,"reaction":"CHRONIC OBSTRUCTIVE AIRWAYS DISEASE EXACERBATED"},{"count":1,"reaction":"ECZEMA"},{"count":1,"reaction":"ERYSIPELAS"},{"count":1,"reaction":"OEDEMA PERIPHERAL"},{"count":1,"reaction":"OSTEONECROSIS"},{"count":1,"reaction":"RASH ERYTHEMATOUS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Locatop@","genericName":"Locatop@","companyName":"Pierre Fabre Medicament","companyId":"pierre-fabre-medicament","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Locatop is a topical corticosteroid that reduces inflammation and immune response in skin conditions by binding to glucocorticoid receptors. Used for Inflammatory skin conditions (eczema, dermatitis, psoriasis), Localized inflammatory dermatological disorders.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}